Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands

Objective: There is limited evidence on patients' adherence and the impact of the prescribed dosing regimen in non-vitamin-K oral anticoagulants (NOACs). We aimed to assess secondary adherence to NOACs and to determine the impact of the dosing regimen in patients with atrial fibrillation. Methods: Patients using a NOAC between 2009 and 2013 were identified from the nation-wide Swedish Prescribed Drug Register and the Dutch regional IADB.nl database. Patients using a consistent dosage for at least 180 consecutive days were included. Adherence was calculated using the medication possession ratio... Mehr ...

Verfasser: Jacobs, Maartje S
Schouten, Jeroen F
de Boer, Pieter T
Hoffmann, Mikael
Levin, Lars-Åke
Postma, Maarten J
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Reihe/Periodikum: Jacobs , M S , Schouten , J F , de Boer , P T , Hoffmann , M , Levin , L-Å & Postma , M J 2018 , ' Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands ' , Current Medical Research and Opinion , vol. 34 , no. 10 , pp. 1839-1847 . https://doi.org/10.1080/03007995.2018.1459528
Schlagwörter: Adherence / non-vitamin-K oral anticoagulants / anticoagulation / dosing regimen / apixaban / dabigatran / rivaroxaban / DAILY DOSING FREQUENCY / MEDICATION ADHERENCE / DABIGATRAN ADHERENCE / RISK FACTOR / WARFARIN / STROKE / IMPACT / PERSISTENCE / COHORT
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26824878
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/2d9781ce-1b22-40c5-8b7b-6e3bcaa63d38

Objective: There is limited evidence on patients' adherence and the impact of the prescribed dosing regimen in non-vitamin-K oral anticoagulants (NOACs). We aimed to assess secondary adherence to NOACs and to determine the impact of the dosing regimen in patients with atrial fibrillation. Methods: Patients using a NOAC between 2009 and 2013 were identified from the nation-wide Swedish Prescribed Drug Register and the Dutch regional IADB.nl database. Patients using a consistent dosage for at least 180 consecutive days were included. Adherence was calculated using the medication possession ratio (MPR) and adjusted for overlapping dates. Adherence was defined as a MPR >= 0.8. Sensitivity analyses were performed using a MPR >= 0.9. Logistic regression was performed to compare secondary adherence and to explore the influence of the dosing regimen. Results: A total of 5254 Swedish and 430 Dutch NOAC users were included. The mean MPR was 96.0% (SD 7.8%) in Sweden and 95.1% (SD 10.1%) in the Netherlands. Multivariable logistic regression analysis showed that a twice daily regimen had a lower likelihood of being secondary adherent compared to a once daily regimen in Sweden (odds ratio [OR] 0.21 [95% CI 0.12-0.35]). Limitations: The influence of selection bias introduced by the inclusion criterion of >= 2 dispensations covering at least 180 days could not be excluded. Conclusions: This study demonstrated that secondary adherence was high in this specific setting among patients with at least two initial dispensations of a NOAC covering a minimum of 180 days. The use of NOACs in a once daily regimen showed higher adherence compared to a twice daily regimen.